159225-99-7 Usage
Uses
Used in Pharmaceutical Industry:
5-Oxo-Zaleplon is used as an active metabolite for the treatment of insomnia. As a metabolite of Zaleplon, it contributes to the sedative and hypnotic effects of the parent compound, helping to alleviate sleep disorders and improve sleep quality.
Used in Research and Development:
5-Oxo-Zaleplon is also utilized in the research and development of new therapeutic strategies targeting the GABAA receptor. Understanding the properties and effects of this metabolite can lead to the development of more effective and safer treatments for insomnia and other related conditions.
Used in Drug Metabolism Studies:
In the field of pharmacology, 5-Oxo-Zaleplon serves as a subject of study for understanding drug metabolism and the role of metabolites in the overall efficacy and safety of medications. This knowledge can be applied to optimize drug design and dosing regimens, ultimately benefiting patients and healthcare providers.
Check Digit Verification of cas no
The CAS Registry Mumber 159225-99-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,2,2 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 159225-99:
(8*1)+(7*5)+(6*9)+(5*2)+(4*2)+(3*5)+(2*9)+(1*9)=157
157 % 10 = 7
So 159225-99-7 is a valid CAS Registry Number.
159225-99-7Relevant academic research and scientific papers
Yang, Xin,Johnson, Nathaniel,Di, Li
, p. 1627 - 1630 (2019)
Hydralazine has been reported as a selective mechanism-based inactivator of aldehyde oxidase (AO) and it is widely used in the pharmaceutical industry for reaction phenotyping to estimate fraction metabolized by AO and to identify AO substrates. In this study, however, hydralazine was found to inhibit CYP1A2, 2B6, 2D6, and 3A in human suspension hepatocytes under reaction phenotyping assay conditions, at concentrations that chemically knocked out most of the AO activities (≥50 μM). Furthermore, hydralazine is a time-dependent inhibitor of CYP1A2. Based on these findings, precautions need to be taken when using hydralazine as an AO inhibitor for in vitro studies because fraction metabolized by AO is likely to be overestimated and the likelihood of false positives in identifying AO substrates increases.
